Form 4: CME Group Director Daniel Kaye Reports Pre-Planned Stock Sale Valued Over $141,000

CME Group Director Daniel G. Kaye reported the sale of 500 shares of Common Stock Class A at a price of $282.4193 per share on May 22, 2025, reducing his direct beneficial ownership to 3,668 shares, as part of a pre-scheduled Rule 10b5-1 plan.

Summary

• Daniel G. Kaye, a Director of CME Group Inc. (CME), reported a transaction involving the company's Common Stock Class A.
• On May 22, 2025, Mr. Kaye disposed of 500 shares of Common Stock Class A.
• The shares were sold at a price of $282.4193 per share.
• The total value of the shares sold is approximately $141,209.65 (500 shares * $282.4193).
• Following this transaction, Daniel G. Kaye directly beneficially owns 3,668 shares of Common Stock Class A.
• The transaction was made pursuant to a Rule 10b5-1(c) contract, instruction, or written plan, indicating it was a pre-scheduled sale.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. While it's an insider sale, the fact that it was executed under a Rule 10b5-1 plan mitigates the typical negative interpretation of insider selling, suggesting it was a pre-scheduled financial event rather than a reaction to new company-specific negative news.

Positives

• The sale was conducted under a Rule 10b5-1 plan, indicating it was a pre-scheduled transaction and not necessarily a reflection of new negative sentiment regarding the company's prospects or immediate market conditions.

Negatives

• Daniel G. Kaye, a Director, disposed of 500 shares of CME Group Inc. Common Stock Class A, reducing his direct beneficial ownership.

Risks

• While the sale was pre-planned, any insider selling, regardless of the reason, can sometimes be misinterpreted by the market as a negative signal, potentially leading to short-term price volatility.

Future Outlook

This Form 4 filing does not provide any forward-looking statements or guidance regarding the company's future outlook.

Industry Context

This filing is a routine disclosure of an insider stock transaction for CME Group Inc., a leading derivatives marketplace. Such transactions are common and typically reflect individual financial planning rather than broader industry trends, especially when executed under a Rule 10b5-1 plan.

Stakeholder Impact

• Shareholders may observe the reduction in a director's direct beneficial ownership, though the pre-planned nature of the sale under a Rule 10b5-1 plan mitigates concerns about its implications for the company's future performance.

Key Dates

Recommendation

Keywords

CME Group, CME, Daniel G. Kaye, Form 4, insider transaction, stock sale, beneficial ownership, Rule 10b5-1 plan, director